Esperion’s ‘lipid lurkers’ take on cardiovascular disease

cafead

Administrator
Staff member
  • cafead   Jul 16, 2024 at 12:22: PM
via Esperion Therapeutics has debuted a promotional push for its FDA-approved non-statin low-density lipoprotein (LDL) drugs Nexlizet and Nexletol. The campaign features “lipid lurkers,” mischievous cartoon creatures

article source